Evidence map›Paper›PMID 38123736›Full record

ArticleCommunications medicine2023

Large-scale deep learning analysis to identify adult patients at risk for combined and common variable immunodeficiencies.

Giorgos Papanastasiou, Guang Yang, Dimitris I Fotiadis, Nikolaos Dikaios, Chengjia Wang, Ahsan Huda, Luba Sobolevsky, Jason Raasch, Elena Perez, Gurinder Sidhu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Communications medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Giorgos PapanastasiouPfizer Inc, New York, NY, USA. georgios.papanastasiou@pfizer.com.ORCID http://orcid.org/0000-0002-1939-296X
Guang YangNational Heart and Lung Institute, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-7344-7733
Dimitris I FotiadisDepartment of Biomedical Research, Institute of Molecular Biology and Biotechnology, FORTH, Ioannina, Greece.
Nikolaos DikaiosMathematics Research Center, Academy of Athens, Athens, Greece.
Chengjia WangSchool of Mathematical and Computer Sciences, Heriot Watt, Edinburgh, UK.
Ahsan HudaPfizer Inc, New York, NY, USA.
Luba SobolevskyImmunoglobulin National Society, Woodland Hills, CA, USA.
Jason RaaschMidwest Immunology Clinic, Plymouth, MN, USA.
Elena PerezAllergy Associates of the Palm Beaches, North Palm Beach, FL, USA.
Gurinder SidhuPfizer Inc, New York, NY, USA.
Donna PalumboPfizer Inc, New York, NY, USA.
Pfizer (United States) · USAcademy of Athens · GRAllergy Associates of the Palm Beaches · USHeriot-Watt University · GBKing's College London · GBUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary immunodeficiency (PI) is a group of heterogeneous disorders resulting from immune system defects. Over 70% of PI is undiagnosed, leading to increased mortality, co-morbidity and healthcare costs. Among PI disorders, combined immunodeficiencies (CID) are characterized by complex immune defects. Common variable immunodeficiency (CVID) is among the most common types of PI. In light of available treatments, it is critical to identify adult patients at risk for CID and CVID, before the development of serious morbidity and mortality.

methodsWe developed a deep learning-based method (named "TabMLPNet") to analyze clinical history from nationally representative medical claims from electronic health records (Optum® data, covering all US), evaluated in the setting of identifying CID/CVID in adults. Further, we revealed the most important CID/CVID-associated antecedent phenotype combinations. Four large cohorts were generated: a total of 47,660 PI cases and (1:1 matched) controls.

resultsThe sensitivity/specificity of TabMLPNet modeling ranges from 0.82-0.88/0.82-0.85 across cohorts. Distinctive combinations of antecedent phenotypes associated with CID/CVID are identified, consisting of respiratory infections/conditions, genetic anomalies, cardiac defects, autoimmune diseases, blood disorders and malignancies, which can possibly be useful to systematize the identification of CID and CVID.

conclusionsWe demonstrated an accurate method in terms of CID and CVID detection evaluated on large-scale medical claims data. Our predictive scheme can potentially lead to the development of new clinical insights and expanded guidelines for identification of adult patients at risk for CID and CVID as well as be used to improve patient outcomes on population level.

Identifiers

PMID38123736
PMCPMC10733406
OpenAlexW4390013738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.